Nature Communications (Dec 2019)
LRIG1 is a pleiotropic androgen receptor-regulated feedback tumor suppressor in prostate cancer
- Qiuhui Li,
- Bigang Liu,
- Hsueh-Ping Chao,
- Yibing Ji,
- Yue Lu,
- Rashid Mehmood,
- Collene Jeter,
- Taiping Chen,
- John R. Moore,
- Wenqian Li,
- Can Liu,
- Kiera Rycaj,
- Amanda Tracz,
- Jason Kirk,
- Tammy Calhoun-Davis,
- Jie Xiong,
- Qu Deng,
- Jiaoti Huang,
- Barbara A. Foster,
- Abhiram Gokhale,
- Xin Chen,
- Dean G. Tang
Affiliations
- Qiuhui Li
- Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center
- Bigang Liu
- Department of Epigenetics and Molecular Carcinogenesis, University of Texas M.D. Anderson Cancer Center
- Hsueh-Ping Chao
- Department of Epigenetics and Molecular Carcinogenesis, University of Texas M.D. Anderson Cancer Center
- Yibing Ji
- Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center
- Yue Lu
- Department of Epigenetics and Molecular Carcinogenesis, University of Texas M.D. Anderson Cancer Center
- Rashid Mehmood
- Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center
- Collene Jeter
- Department of Epigenetics and Molecular Carcinogenesis, University of Texas M.D. Anderson Cancer Center
- Taiping Chen
- Department of Epigenetics and Molecular Carcinogenesis, University of Texas M.D. Anderson Cancer Center
- John R. Moore
- Department of Epigenetics and Molecular Carcinogenesis, University of Texas M.D. Anderson Cancer Center
- Wenqian Li
- Department of Epigenetics and Molecular Carcinogenesis, University of Texas M.D. Anderson Cancer Center
- Can Liu
- Department of Epigenetics and Molecular Carcinogenesis, University of Texas M.D. Anderson Cancer Center
- Kiera Rycaj
- Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center
- Amanda Tracz
- Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center
- Jason Kirk
- Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center
- Tammy Calhoun-Davis
- Department of Epigenetics and Molecular Carcinogenesis, University of Texas M.D. Anderson Cancer Center
- Jie Xiong
- Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center
- Qu Deng
- Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center
- Jiaoti Huang
- Department of Pathology, Duke University of School of Medicine
- Barbara A. Foster
- Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center
- Abhiram Gokhale
- Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center
- Xin Chen
- Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center
- Dean G. Tang
- Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center
- DOI
- https://doi.org/10.1038/s41467-019-13532-4
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 19
Abstract
LRIG1 is a tumour suppressor in several cancers. Here, the authors show that androgen receptor directly transactivates LRIG1 which then antagonises ERBB signalling and c-Myc expression to inhibit prostate tumorigenesis.
